![]() | |
Clinical data | |
---|---|
Pronunciation |
/ˌsoʊtəɡlɪˈfloʊzɪn/ SOH-tə-gli-FLOH-zin |
Trade names | Zynquista, Inpefa |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.231.837 |
Chemical and physical data | |
Formula | C21H25ClO5S |
Molar mass | 424.94 g·mol−1 |
3D model ( JSmol) | |
| |
|
Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. [1]
The most common side effect is genital infection in women. [2] Other common side effects include diabetic ketoacidosis, diarrhea, and genital infection in men. [2]
Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista, for the treatment for type 1 diabetes, [2] and in the United States in May 2023, to reduce the risk of death due to heart failure. [1] [3] The marketing authorization for sotagliflozin was withdrawn in the EU in August 2022. [2]
In the United States, sotagliflozin is indicated to reduce the risk of cardiovascular death. [1] Sotaglifozin is a sodium-glucose co-transporter 1 and 2 inhibitor that reduces both postprandial glucose and insulin levels by delaying intestinal glucose absorption, decreases gastric inhibitory polypeptide, and elevations in glucagon-like peptide and peptide yy levels are consistent with local inhibition of intestinal SGLT1. [4] Combination of insulin with sotaglifozin 200 and 400 mg led to a significant lowering of systolic and diastolic blood pressure and multiple indirect markers of arterial stiffness, including pulse pressure, without changes in pulse rates. [5] Also, it decreased the incidence of myocardial infarction and stroke, pointing to a potential side effect of SGLT1 inhibition. [6]
The US Food and Drug Administration (FDA) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Lexicon Pharmaceuticals. [7] [8] [9]
In May 2023 the US FDA approved Inpefa (sotagliflozin), a once-daily oral tablet, to decrease the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk. [10]
![]() | |
Clinical data | |
---|---|
Pronunciation |
/ˌsoʊtəɡlɪˈfloʊzɪn/ SOH-tə-gli-FLOH-zin |
Trade names | Zynquista, Inpefa |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.231.837 |
Chemical and physical data | |
Formula | C21H25ClO5S |
Molar mass | 424.94 g·mol−1 |
3D model ( JSmol) | |
| |
|
Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. [1]
The most common side effect is genital infection in women. [2] Other common side effects include diabetic ketoacidosis, diarrhea, and genital infection in men. [2]
Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista, for the treatment for type 1 diabetes, [2] and in the United States in May 2023, to reduce the risk of death due to heart failure. [1] [3] The marketing authorization for sotagliflozin was withdrawn in the EU in August 2022. [2]
In the United States, sotagliflozin is indicated to reduce the risk of cardiovascular death. [1] Sotaglifozin is a sodium-glucose co-transporter 1 and 2 inhibitor that reduces both postprandial glucose and insulin levels by delaying intestinal glucose absorption, decreases gastric inhibitory polypeptide, and elevations in glucagon-like peptide and peptide yy levels are consistent with local inhibition of intestinal SGLT1. [4] Combination of insulin with sotaglifozin 200 and 400 mg led to a significant lowering of systolic and diastolic blood pressure and multiple indirect markers of arterial stiffness, including pulse pressure, without changes in pulse rates. [5] Also, it decreased the incidence of myocardial infarction and stroke, pointing to a potential side effect of SGLT1 inhibition. [6]
The US Food and Drug Administration (FDA) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Lexicon Pharmaceuticals. [7] [8] [9]
In May 2023 the US FDA approved Inpefa (sotagliflozin), a once-daily oral tablet, to decrease the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk. [10]